Stoke Therapeutics, Inc.STOKNASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank68
3Y CAGR+43.0%
5Y CAGR+2.0%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
+43.0%/yr
vs -21.7%/yr prior
5Y CAGR
+2.0%/yr
Recent acceleration
Acceleration
+64.7pp
Accelerating
Percentile
P68
Within normal range
vs 5Y Ago
1.1x
Modest growth
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 10.83% |
| Q3 2025 | 44.09% |
| Q2 2025 | -20.87% |
| Q1 2025 | 39.50% |
| Q4 2024 | 5.49% |
| Q3 2024 | 7.85% |
| Q2 2024 | -5.58% |
| Q1 2024 | 3.08% |
| Q4 2023 | 7.74% |
| Q3 2023 | -1.53% |
| Q2 2023 | 4.76% |
| Q1 2023 | -6.93% |
| Q4 2022 | 3.71% |
| Q3 2022 | 9.22% |
| Q2 2022 | -0.03% |
| Q1 2022 | 14.30% |
| Q4 2021 | 10.06% |
| Q3 2021 | 1.87% |
| Q2 2021 | 42.19% |
| Q1 2021 | 11.33% |
| Q4 2020 | 9.80% |
| Q3 2020 | 1.77% |
| Q2 2020 | 10.44% |
| Q1 2020 | 1.78% |
| Q4 2019 | 8.76% |
| Q3 2019 | 8.22% |
| Q2 2019 | 45.73% |
| Q1 2019 | 37.58% |
| Q4 2018 | 34.89% |
| Q3 2018 | 17.96% |
| Q2 2018 | 50.80% |
| Q1 2018 | 0.00% |